Escitalopram (Lexapro) for the Treatment of Postpartum Depression (LexaproPPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00833469|
Recruitment Status : Completed
First Posted : February 2, 2009
Results First Posted : August 6, 2014
Last Update Posted : August 6, 2014
|Condition or disease||Intervention/treatment||Phase|
|Postpartum Depression||Drug: Escitalopram||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Escitalopram for the Treatment of Postpartum Depression|
|Study Start Date :||January 2009|
|Primary Completion Date :||April 2011|
|Study Completion Date :||April 2011|
Flexible dose escitalopram 10mg
Once daily by mouth
Other Name: Lexapro
- Change in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 8 weeks ]The Montgomery-Åsberg Depression Rating Scale is a widely used 10-item clinician-rated scale that describes the severity of depressive symptoms (range 0-60, higher score indicates greater symptom burden).
- Change in Edinburgh Postnatal Depression Scale (EPDS) [ Time Frame: 8 weeks ]The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-report used to measure postpartum depression (range 0-30, higher score indicates greater symptom burden). A score of >9 is indicative of perinatal major depression.
- Change in Beck Anxiety Inventory (BAI) [ Time Frame: 8 weeks ]Beck Anxiety Inventory (BAI): The BAI is a 21-item self-report questionnaire measuring typical symptoms of anxiety during the past week (range 0-63, higher score indicates greater anxiety).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00833469
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Marlene P Freeman, MD||Massachusetts General Hospital|